An Overview On :- Drug Regulatory Affairs

Uddhav Gorakh Ghalme , Prof Bhavna Hon , Dr.MeghaSalve

Shivajirao Pawar College Of Pharmacy, Pachegaon Dist:-Ahemadnagar

Corresponding Author

Deparment Of Pharmaceutics

Shivajirao Pawar College Of Pharmacy Pachegaon,Tel .Newasa Dist Ahemadnagar , Maharashtra 422602

Email Id :- Uddhavghalme67@Gmail.Com

Mobile No :- 7218973497

Abstract

The regulatory standards for therapeutic product marketing authorization are under the purview of regulatory affairs. Numerous factors that affect the development, regulation, and value proposition ofnew medicinal items are being faced by this profession. Global megatrend transformations, including the emergence of the green economy and changes in geopolitics, have highlighted the significance of manufacturing and supply chain security, as well as minimizing the environmental effects of product creation. The COVID-19 pandemic has expedited changes brought about by scientific advancements, digital disruption, a renewed emphasis on the patient's centrality in all stages of medicinal product development, and increased cooperation betweennational regulatory bodies. The different trends that are influencing thecreation of novel treatments will be covered in this article.

Keywords: *Regulatory authorities, Regulatory agencies, Pharmacy schedule,Pharmacy policy, Worldwide regulatory agencies .*

> Introduction :-



In addition, regulatory agencies are cooperating more and creating work-sharing, reliance, and collaborative reviews to facilitate the review of these novel productscoming through the regulatory system (4.5). These areas of study include
regulatory affairs, regulatory science, drug development, and the future treumber of cell and gene therapies coming to market and are delivering more benefits for patients (2.3).

The development of a new chemical might cost several million dollars or rupees, and any mistake has a greater negative effect on the standing of the company.
Since medications are essential to human existence, laws governing their quality, safety, and effectiveness are necessary. The sole person who has full responsibilityfor keeping all records up to date and keeping products in compliance is the
regulatory affairs specialist. One of the regulatory specialist's essential tasks is

> Pharmaceutical drug regulatory affairs :-

The relatively recent field of regulatory affairs emerged from governments' efforts to safeguard the public's health by regulating the efficacy and safety of goods in a variety of industries, including pharmaceuticals, veterinary care, medical devices, pesticides, agrochemicals, cosmetics, and complementary and alternative
therapies (8)

> Regulators affair profession needs:-

Despite having two significant international professional membership associations, the (healthcare) regulatory affairs profession is still in its infancy. The Organization for Professionals in Regulatory Affairs
(TOPRA) and the Regulatory Affairs Professionals Society (RAPS). The CanadianAssociation of Professional Regulatory Affairs, or CAPRA.4-7, is the main professional
membership society in Canada. In the current competitive landscape, a product's and thus the business's success depends on how quickly it can reach the market. For this reason, the company's ability to conduct its regulatory affairs operations properly is extremely important financially. A marketing application may not be positively evaluated in a timely manner if data reporting is inadequate. It may have cost millions of pounds, euros, or dollars to create a new drug, and there might have even been a three-month wait to introduce it.

> Historical overview pharmaceutical industries and regulatoryaffairs:- :

During 1950s, multiple tragedies
i.e., sulfanilamide elixir, vaccine tragedy and thalidomide tragedy have resulted in substantial increase of legislations for drug products quality, safety and efficacy.
This has also resulted into stricter norms for Marketing Authorization
(MA) and Good Manufacturing Practices (GMPs). To understand the chronological development of the modern era Of pharmaceutical industry and regulatory framework, we will glance through the historical evolution of regulations In USA, Europe and India. Let us see what happened in USA, Europe and India(10**)**

> Organization structure of regulatory affairs:-

Not consistent between the businesses and always evolving Regulatory affairs related to manufacturing sites, drug agencies, global regulation, regional
regulation, local regulation, and manufacturing site regulation The size, nature, and culture of the business, as well as the individuals involved, will determine the structure. Senior Regulatory Affairs experts are increasingly being elevated to boardroom positions due to the function's significance, which allows them to advise on and further impact the strategic decisions of their organizations (11).

> Scope of regulatory affairs in pharmaceutical industry:

Since the early 20th century, there has been an increase in the regulation ofmedical items.
Worldwide, the number of nations establishing regulatory agencies is always
rising. Those that have already been created are trying to coordinate with foreign organizations by

reforming their systems.1 . Medical devices, biotechnology, and pharmaceuticals are among of the world's most heavily regulated businesses.
Professionals in regulatory affairs (RA) work for the government, the pharmaceutical industry, academic research centers, and healthcare facilities.
With a compound annual growth rate (CAGR) of more than 13% during the previous five years, the pharmaceutical sector in India is one of the fastestgrowingin the country. During the next ten years, growth in this industry is predicted to accelerate. It ranks first and has an approximate worth of $8.0 billion.

> Regulation of Drug products involve following areas –

Non-clinical and Clinical Drug Development Guidelines Licensing (Patent) Drug Registration Manufacturing Quality and safety Guidance Pricing and Trademark Marketing, Import and Distribution of Drug products Pharmacovigilance (Adverse Drug Reactions monitoring)

>Regulatory Authorities –

With public health as the top priority, medications, drug products, and medicaldevices that are available for use in humans, animals, or both must be safe for their intended purpose in addition to being effective. Numerous territorial regulatory bodies were established in order to guarantee this. Pharmaceuticals and Medical Devices Agency (PMDA, Japan), Central Drugs Standard Control Organization (CDSCO, India), Therapeutic Goods Administration (TGA, Australia), Health Canada (Canada), European Medicines Agency (EMA, European Union), World Health Organization (WHO), and United States Food and Drug Administration (USFDA, United States) are some of the major regulatory agencies.

It was noted that different regulatory norms apply to different territories, which made universal harmonization necessary. In order to bring together various regulatory bodies worldwide and establish ICH Guidelines for pharmaceutical drug product development, the United States, Europe, and Japan united to found the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) in 1990. With the goal of achieving greater harmonization in the development andregistration of pharmaceuticals with a higher level of safety, efficacy, and quality globally, the ICH has gradually changed since its founding. Notwithstanding the fact that ICH has harmonized drug regulatory features globally, regional regulatoryagencies are still essential to the licensing of drugs throughout the region.(13).

> Evolution of regulatory affairs:

Many catastrophes in the 1950s were caused by misinterpretations made by workers during the manufacturing process and intentional additions of tainted materials into pharmaceutical products, which led to patient executions.
Following a great deal of incidents, the regulatory authorities introduced new laws and regulations that will improve the items' efficacy, safety, and quality. Once more, this is refined into strict guidelines for Good Manufacturing Practices (GMPs) and Marketing Authorization (MA). That is the THALIDOMIDE, VACCINE, and SULPHANILAMIDE ELIXIR tragedy began as the Bureau of Chemistry in 1906 and was primarily responsible for monitoring claims made regarding food and medications. Components.. At the time, new medication marketing did not require official government permission. The tragedies sparked a public uproar that resulted in the 1983 Food Drug & Cosmetics Act, which granted the FDA the authority to oversee the safety of novel drugs.

> International Regulatory Environment:

The Laws of Kashrut, or Good Manufacturing Practices, date back to the Old Testament. The fundamental guidelines for conducting medical experiments on humans were established by the Nuremberg Code of 1947 on Permissible Medical Experiments7, which was followed by the Declaration of Helsinki (1964), the Belmont Report of USA9 (1978), WHO GCP10 (1995), and ICH GCP11 in 1996. Canada implemented the QUAD standards in 1959, marking the inception of the contemporary era's first widely recognized Drug GMP. GMPs from the USA in 1963 and the UK in 1972 came next.

> Future developments:

As the best model for bringing new healthcare goods to market in a timely mannerwith reasonable safety, the Regulatory Affairs Profession ultimately counts on making overtures to regulation for all healthcare items. Departments of regulatory affairs are growing within companies. Some companies choose to

redistribute or outsource regulatory affairs to outside amenity providers due to the ever- changing nature of assets and the necessity of meeting regulatory requirements.

The department of regulatory affairs is constantly growing and expanding, and it is the one that is marginally impacted by alliances and investments, in addition to downturns. Global excellence harmonization has produced reconcilable solicitations. In regulatory surrender and as a result (14)

> RESPOSIBILITIES OF REGULATORY AFFAIRS AGENCIES:- 3

1) Making certain that their businesses adhere to all rules and legislation relevantto their industry.

2)Collaborating with employees of federal, state, and local regulatory bodies oncertain matters pertaining to their business.

3) Advising businesses on the laws and conditions that could impact the proposed activity they want to do.

4) Stay abreast of global regulations, standards, and consumer behavior.

5) Stay current with a company's product line.

6) Gather, compile, and assess the scientific data being generated by their colleagues in research and development.

7) Create regulatory strategy for all relevant regulatory submissions, including contract projects and/or domestic and overseas projects.

8) In accordance with the organization, coordinate, prepare, and examine all pertinent papers, such as dossiers, and submit them to regulatory agencieswithin a given time limit.

9) Draft and examine RA-related SOPs. BMR, MFR, change control, and other pertinent documents are reviewed.

10) Track the status of each registration submission.

11) Keep track of approved applications and registration fees received in relation to DMF submissions (15)

> NATIONAL REGULATORY AUTHORITY:-

Central Drug Standard Control Organization (CDSCO) is located in India. India's Drug Controller General (DCGI)
FDA (United States Food and Drug Administration)

Europe: - European Medicines Quality Directorate (EDQM) Evolution
of European Medicine Agency (EMEA) (2)
The Modern Scientific System of Medicine has established a statutory board and two committees named the Drugs Technical Advisory Board (DTAB) and the Drug Consultative Committee (DCC), respectively, to aid in the regulation process anddecision-making of DCGI. Additionally, the Central Drug Laboratory at the CentralResearch Institute in Kasauli, HP, is available for drug testing, as is the Indian traditional medical system. The DTAB is made up of technical specialists who provide state and federal governments with advice on technical issues related todrug control. Any changes to drugs and cosmetics are made with this board's consultation first.Drug Control measures are ensured throughout India by the
Drug Consultative Committee, whose members are state and federal drug control officials. It serves as an advisory council to the State, Federal, and DTAB
governments (16).

> Which are the top drug regulatory agencies

Food and Drug Administration (FDA) in the US

The Pharmaceutical and Medical Devices Agency (PMDA) of Japan and the European Medicines Agency (EMA)

The Central Organization for Standard Control of Drugs (CDSCO)Swiss medic is a Swiss company.
The Therapeutic Goods Administration (TGA) in Australia (17

> Regulatory Affair Profession:-

It takes many years to bring a new drug to market; for this reason, it is crucial thatthe process be handled efficiently from start to finish in order to comply with regulatory standards and enable a positive assessment of quality, efficacy, and safety as soon as feasible. Ten. A drug regulatory affairs (DRA) expert is crucial to the process at every stage, from creating efficient regulatory strategies when a new molecule is discovered to organizing post-marketing operations. In the pharmaceutical industry, a DRA professional's primary responsibilities include obtaining permission for drug submissions from the Health Therapeutic Products Program and making ensuring that marketed and experimental drugs comply withall applicable regulations, guidelines, and policies, as well as the Food and Drug Act. F.

The DRA professional is required to have both a strong scientific background and extensive knowledge of both domestic and international legislation in order to be considered for this role. The regulatory landscape is changing quickly in favor of mutual recognition between various health authorities worldwide and global harmonization (the TPP has recently adopted several ICH guidelines). As a result, it is becoming increasingly difficult for DRA professionals to stay up to date on policy changes and ascertain how they will impact the approval process. As a result, during the past ten years, the significance of DRA in the creation and authorizationof novel medications has grown dramatically.18)

> The role of the regulatory affairs department

A pharmaceutical company's regulatory affairs (RA) division is in charge of gettingnew drugs approved and making sure that approval is upheld for as long as the business wishes to keep the product on the market. In order to make sure that theproject plan accurately predicts what the regulatory authority will need before approving the product, it acts as an interface between the project team and the regulatory authority and as a channel of communication with the regulatoryauthority as the project moves forward. Keeping up with the latest rules, regulations, and other regulatory information is RA's duty. Regulatory bodiestypically expect companies to determine how to interpret such laws and recommendations, which often allow for some freedom. The RA department is crucial in helping the project team understand the regulations by providing guidance. Good working relationships with authorities are crucial during the



development process, for example, to address matters like formulation development, clinical trial plans, and deviations from guidelines.19)

> Skills for the future regulatory affairs workforce

The regulatory affairs team will be impacted by these advancements in medicine, healthcare, and the pharmaceutical and medical device industries. With the advent of digital technologies and automation, the old heavy "task"based workload will change and call for broader strategic leadershipabilities. To progress in their careers, regulatory professionals must consequently possess the abilities, know-how, and self-development mentality that will enable them to grow as individuals. According to experts, the modernworkplace is volatile, unpredictable, complex, and ambiguous (VUCA), and the worldwide pandemic has created a "new normal" where these elements are emphasized (20.21,)

> Megatrends

Regulatory affairs professionals can better handle the future implications on their roles by having an understanding of how global megatrends are changing.
Megatrends are widespread patterns that could take years to develop and have the power to drastically alter society (22.23)



> ACTIVITIES OF PHARMA REGULATORY AFFAIRS IN INDUSTRIES:-

India is growing in popularity as a location for R&D and clinical trials. The pharmaceutical sector in India is growing in breadth as a result of industry
development. Mumbai has a lot of regulatory problems. 7, 9, The first stage of theproduct life cycle is

1. business development.

2. Development of New Products

3. Production

Phase 1:

> Business Development:-

Plans development plans show that the business is defining its export pricing strategies, export commitments, export reasons, export financing options, potential markets and customers for support, foreign trade methods,
transportation methods, international partnerships, and investment capabilities.

The International Business Development program's primary goal is to get your company ready to go global.

The following broad operating concepts guide the creation of an internationalbusiness development plan:

1. Goods or services: Carefully considering a profitable product to provide in themarket is necessary when choosing the best one and determining which ones have export potential.

2.planning: The planning stage looks at potential outcomes and future companyactivities.

3. Goal Setting: Creating objectives to plan for entering international markets andto set goals for your organization might be difficult. Companies ought to set both short- and long-term objectives for their operations.

> **Phase 2: Development of new products:-**

The following are the primary purposes of coordination for the creation of newproducts:formulation and assessment of the development of the formulation's viability International Regulatory Affairs: Product Design prerequisites

Global Business Development Unit

When creating new generic medications, the product development teamfrequently uses the following operational tools:

Confirmation and Formulary Information Request Form for New Products (NPRF) Requests for New Product Development or Sign Up with the Company Selling the

Current Products

> **This form is mainly consists of the following:-**

- Product Name
- Master List
- Dosage Form
- Administration Route System of Container Closure
- Materials for Packing
- Information about the market.
- Guideline for Regulation

> **New product development process mainly includes NextSteps:**

1) Pre-Formulation Planning:

Following formal approval of the product development, the product developmentteam As the inquiry gets underway, the following will be guaranteed:

- Creative product development
- Physicochemical parameters
- Systems for closing containers
- Studies on stability
- Storage circumstances

The next phase is the preparation of a summary report based on the data that isavailable.

1. Complete Formulation and Batch Examination:

➢ Pre-formulation study data analysis, reasoning, and first-phase planning will allbe included in the Final Formulation Study Plan Last formulation analysis.

1. Humidity and Temperature of the Batch
2. The duration of this three-group stability study is six months.
3. The subsequent actions will be taken for additional development when thestability group's 3- to 6month stability data has been confirmed.
4. The following documents are located in the "Records" section:
   1) Product Development Report
   2) Literature Investigation Report
5. Sample Test Report for Innovators
6. Report on Drug Excipient Compatibility 7. Laboratory Test Log for Product Registration > **Records**:

Phase 3: Manufacturing:-

Two categories of non-pharmaceutical products are made using the sterile process: sterile products. To reduce the danger of pyrogenic, particle, and microbiological contamination, sterile product manufacturing must adhere tostrict guidelines.

Everything is dependent upon the personnel's qualifications, experience, anddisposition. Quality control is very crucial, and as a result, manufacturing processes and procedures must be rigorously adhered to. Testing of the final process or product should not be done solely based on sterility or other qualityrelated factors (24).

> **Regulatory Affairs plays a crucial role in the pharmaceuticalindustry:-**

Particularly during the lengthy, intricate, incredibly expensive, yet essential process of drug development. Experts in regulatory affairs are involved in every stage of the development process, continuing long after a drug is approved and brought to market. They have a special blend of managerial and scientific abilitiesto accomplish a crucial business objective in a drug development company.

At such companies, the Regulatory Affairs department offers technical and strategic guidance at the highest level. In this sense, they significantly advance the company's overall performance as well as the success of a research program froma scientific and commercial standpoint.

Seeking external RA team members with specialized knowledge, many pharmaceutical businesses make sure that products are designed, manufactured, and managed at all desired levels of quality, safety, and efficacy. Skilled consultants to guarantee that all deadlines are adhered to, high standards are maintained, and filing and submission objectives are fulfilled.



Figure

1) Approximately 15 years have elapsed since the beginning of the R&D phase and, typically, the starting of the patent application, when a medicine is introduced to the market. This demonstrates the drawn-out and expensive process a new drug must go through during the R&D, clinical, and drug registration phases. By involving regulatory affairs experts as soon as possible, this can help to avoid needless delays in the development and registration process and will eventually lead to the drug's approval and the beginning of its commercialization. Figure 1: Approximately 15 years have elapsed since the beginning of the R&D phase and, typically, the starting of the patent application, when a medicine is

introduced to the market. This demonstrates the drawn-out andexpensive process a new drug must go through during the R&D, clinical, and drugregistration phases. By involving regulatory affairs experts early on, developers and regulators can avoid needless delays in the process, which will speed up approval and the start of the medicinal product's commercialization. Pharmaceutical item. (25)

> ***Japanese Regulatory Approval of Pharmaceuticals:-***

MHLW is in charge of regulatory affairs for pharmaceuticals. From preclinical to postmarking surveillance, new medicinal products are reviewed and consulted by the Pharmaceutical and Medical Devices Agency (PMDA, Kiko), an external

organization (PMA 2007). GLP and GCP compliance are additional responsibilities of the PMDA. Depending on the kind of drug product (generic, over-the-counter (OTC), and biologics), there are three distinct drug offices.

The Pharmaceutical Affairs Law, last revised in 2005, specifies the data needed to get approval for a drug's manufacture in Japan. The ICH has approved the CTD format for use in Japan. To make the requirements for toxicity tests more in line with international standards, the rules have been reassessed and updated. All toxicity studies in a new drug application should be performed in compliance withGLP standards and the Japanese guidelines applicable to that category of test. The following general test categories must be completed in order to receive marketing approval: skin irritation, carcinogenicity, genotoxicity, repeat dose, toxicity to reproduction and development, and other pertinent toxicity.(26).

> Regulatory Affairs In Research & Development:-

The regulatory affairs staff collaborates closely with marketing and research anddevelopment to create cutting-edge products that capitalize on recent advancements in technology and law to shorten time to market. Since new goodsare anticipated to significantly boost the bottom lines of the company, even slightreductions in time to market translate into substantial increases in sales and profit. Adaptive clinical trial techniques, prompt regulatory authority approval, and process avoidance can speed up the creation of new goods and cut down on expensive mistakes and delays.

Figure 8: RA Profession: Integral to the healthcare products lifecycle

> The other various roles within regulatory affairs:-

- Managing projects; managing submissions; managing maintenance
- A CMC expert
- Clinical and pre-clinical expert
- Labeling specialist
- Information about regulations
- International vs. Domestic regulatory affairs (27)

Reference:-

1.Chisholm, O., & Critchley, H. (2023). Future directions in regulatory affairs. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.1082384

2 .Regenerative medicine: The pipeline momentum builds. (2022, September 6). Alliance for Regenerative Medicine. https://alliancerm.org/sector- report/h12022report/

3.Rives, S., Maude, S. L., Hiramatsu, H., Baruchel, A., Bader, P., Bittencourt, H., Buchner, J., Laetsch, T., De Moerloose, B., Qayed, M., Stefanski, H. E., Davis, K. L., Martin, P. L., Nemecek, E., Peters, C., Yanik, G., Balduzzi, A., Boissel, N., Khaw, S. L.,
… Group, S. (2022). S112: Tisagenlecleucel in pediatric and young adult patients(pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (b-all): Final analyses from the Eliana study. Hemispheres, 6, 13–14. https://doi.org/10.1097/01.hs9.0000843344.19780.98

4 .Claro RA, Spillman D, Hotaki LT, Shum M, Mouawad LS, Santos GM, et al. Project orbis: global collaborative review program. Clin Cancer Res. (2020) 26:6412–6.10.1158/1078-0432.CCR-20-3292 [PubMed] [CrossRef] [Google Scholar]

5. (N.d.). Gov.au. Retrieved October 21, 2023, from https://www.tga.gov.au/international-activities/australia-canadasingaporeswitzerland-united-kingdom-access-consortium

.6. Regulatory Affairs: an overview, by Dolita Shah & MayurMistry.

7. Janjal, V., Dhamodkar, S., Jadhao, Y., Manmode, S., Pawat, A. and Khandelwal,H., 2021. Review article on Recent drug regulatory affairs and CTD module progress review for submission of pharmaceutical product. GSC Biological
Pharmaceutical Sci., 16(3), pp.200-221.

8.Janjal, V., Dhamodkar, S., Jadhao, Y., Manmode, S., Pawat, A. and Khandelwal, H.,2021. Review article on Recent drug regulatory affairs and CTD module progress review for submission of pharmaceutical product. GSC Biological Pharmaceutical Sci., 16(3), pp.200-221.

.9.Quality in the Manufacture of Medicine and other healthcareproducts, Pharmaceutical press, chapter. 3, 29-41.

10. Hasumati Rahalkar, Historical Overview of Pharmaceutical Industry and DrugRegulatory Affairs,

Pharmaceutical Regulatory Affairs, Pharmaceutical Regulatory Affairs: OpenAccess; 2012.

11. Guide to good storage practices for pharmaceuticals. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh Report. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908, Annex 9)

12. Priyanka, M., Bandgar, S., Vijay, P., Rokade, G., Lahu, M., & Hingane, D. (N.d.). Review on regulatory affairs in pharmaceutical industries. Jetir.org. Retrieved October 21, 2023, from https://www.jetir.org/papers/JETIR1908771.pdf

13. (N.d.). Iptsalipur.org. Retrieved October 21, 2023, fromhttps://www.iptsalipur.org/wp-content/uploads/2

14. Priyanka, M., Bandgar, S., Vijay, P., Rokade, G., Lahu, M., & Hingane, D. (N.d.). Review on regulatory affairs in pharmaceutical indusrties. Jetir.org. Retrieved October 21, 2023, from https://www.jetir.org/papers/JETIR1908771.pdf

15. (N.d.). Iptsalipur.org. Retrieved October 21, 2023, fromhttps://www.iptsalipur.org/wp-content/uploads/2

16. (N.d.). Ijrpr.com. Retrieved October 21, 2023, fromhttps://ijrpr.com/uploads/V3ISSUE7/IJRPR5798

17 .Venus Remedies - Indian research driven pharmaceutical company. (N.d.).
Venus Remedies Limited. Retrieved October 21, 2023, from https://venusremedies.com/blog/drug-regulatory-affairs

18. Kawade, D. P., Sahastrabuddhe, M., Dubey, M., Gadodiya, M., Gore, N., & Kinkar, M. (n.d.). An overview

of regulatory affairs in pharmaceutical industries. Jetir.org. Retrieved October 21, 2023, from https://www.jetir.org/papers/JETIR2106052.pdf

19 .Beranger, J. (2016). Management and governance of personal health data. InBig Data and Ethics (pp. 167–236). Elsevier.

20. Casey G., Jr. Leading in a "VUCA" world. Fortune. (2014) 169:75–6. [PubMed][Google Scholar

21. Chisholm O. Curriculum transformation: from didactic to competency-based programs in pharmaceutical medicine. Front Pharmacol. (2019) 10:278.
10.3389/fphar.2019.00278 [PMC free article] [PubMed] [CrossRef] [GoogleScholar]

22. Naughtin C, Hajkowicz S, Schleiger E, Bratanova A, Cameron A, Zamin T, et al.Our Future World: Global Megatrends Impacting the Way We Live Over Coming Decades. Brisbane, QL: CSIRO; (2022). [Google Scholar]

23. Artuso, F., & Guijt, I. (2020). Global Megatrends: Mapping the forces that affectus all. Oxfam.

24. Umesh, I., Shinde, N. D., Prashant Bombale, P., Khandale, R. R., & Khandagale,
S. T. (n.d.). Regulatory affairs in pharmaceutical industries. Ijrti.org. Retrieved October 21, 2023, from https://www.ijrti.org/papers/IJRTI2304191.pdf

25. The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization. (2021, December 8). QbD Group. https://qbdgroup.com/en/blog/the-key-role-of-regulatory-affairs-
inthepharmaceutical-industry-from-drug-development-to-commercialization

26. Béranger, J. (2016). Management and governance of personal health data.In Big Data and Ethics (pp. 167–236). Elsevier.